REDUCTION OF SPIROHYDANTOINS WITH LITHIUM ALUMINIUM HYDRIDE: SYNTHESIS OF SPIROIMIDAZOLIDIN-2"-ONES AND SPIROIMIDAZOLIDINES

Elena de la Cuesta, Paloma Ballesteros and Gregorio G. Trigo\* Departamento de Química Orgánica y Farmacéutica, Facultad de Farmacia, Universidad Complutense, Madrid-3, Spain

<u>Abstract</u> - The behaviour of some spirohydantoins against reduction with lithium aluminium hydride as well as the influence of the  $N_{3}$ -substituent on this reaction are analized.  $N_{3}$ -Unsubstituted spirohydantoins yielded the corresponding spiroimidazolidin-2<sup>-</sup>-ones, while  $N_{3}$ -substituted spirohydantoins originated the spiroimidazolidines. Isomeric ( $\alpha$ and  $\beta$ ) spiroimidazolidin- 2<sup>-</sup>-ones can be prepared by reduction of the suitable epimeric ( $\alpha$  and  $\beta$ ) spirohydantoins.

Scanty and contradictory results have been published in relation to the reduction of hydantoins with lithium aluminium hýdride (LAH). While Wilk et al.<sup>1)</sup> reported a complete reduction of hydantoins to imidazolidines, Marshall<sup>2)</sup> assumed that only one carbonyl group is reduced in this process. The aim of the present paper is to clarify these conflictive results showing the influence not only of the N<sub>3</sub>-substituent but of the overall molecular structure on the hydride attack on some spirohydantoins.

As a general procedure, the spirohydantoins were slowly added into a dried ethereal solution of LAH under reflux with vigorous stirring. After 48 hours, LAH was decomposed according to the Mićović-Mihalović method<sup>3)</sup>. In the case of  $N_{3'}$ -unsubstituted spirohydantoins I-III the insoluble residue in ether was filtered and extracted with absolute ethanol, yielding the spiroimidazolidin-2'-ones IX-XI. When  $N_{3'}$ -substituted spirohydantoins were used the spiroimidazolidines XII-XVI were isolated from the ethereal solution by distillation under vacuum (see Table I).

Ir and <sup>1</sup>H nmr data of spiroimidazolidin-2<sup>-</sup>-ones<sup>4-6</sup>) are in agreement with those reported in the literature for compounds IX and  $x^{12,13}$ .

n e. A define the second of the second second

Ir spectra of spiroimidazolidines XII-XVI showed the absence of CO groups at the 1700 cm<sup>-1</sup> region, and two new methylene groups appeared, in the <sup>1</sup>H nmr spectra, as two singlets at  $\mathcal{S}= 2.40-2.15$  ppm and  $\mathcal{S}= 2.10-2.00$  ppm for all compounds<sup>7-11</sup>.

Monoreduction of  $N_3$ -unsubstituted spirohydantoins could be explained as a consequence of the lower reactivity of the intermediate salt formed from the acidic  $N_1$ , and  $N_3$ , hydrogens of hydantoin ring (Figure 1).



## Figure 1

In this salt the 4<sup>-</sup>-carbonyl group can readily be attacked by the hydride anion. This fact cannot be accomplished on 2<sup>-</sup>-carbonyl group because of its low electrophilic character, due to the resonance anionic  $N_{1^{-}}C_{2^{-}}N_{3^{-}}$  system (Figure 2).



## Figure 2

This low electrophilic character of 2'-carbonyl group was again noticed when the purified cyclopentane-4'-imidazolidin-2'-one (monoreduced compound) was treated with excess LAH in the same conditions as above, the starting material being recovered. This result is in accordance with that reported by Ried et al.<sup>14)</sup> in relation to the reduction of NN-disubstituted ureas, which only underwent reduction when stronger conditions (higher temperature) were used<sup>15,16)</sup>.

The electrophilic character of the 2<sup>-</sup>-carbonyl group can be increased if the N<sub>3<sup>-</sup></sub> is substituted and the intermediate salt can be reduced easier yielding the spiroimidazolidines.

Looking at the yields (see Table 1) we can deduce that in the case of  $N_{3}$ -unsubstituted spirohydantoins the carbocycle size is not very decisive. But in  $N_{3}$ -substituted spirohydantoins, reduction of the two carbonyl groups depends on the carbocycle size as well as the nature of the substituent. Thus, for the same substituent (benzyl) only 28% of spiroimidazolidine XVI was obtained from the more hindered  $N_{3}$ -benzyl-bicyclo [3.2.1] octan-3-spiro-5<sup>-</sup>-hydantoin VIII. When different substituents (benzyl, n-butyl and methyl) were placed on the same spirohydantoin (cyclohexanespirohydantoin) the yields were 60, 27 and 40%, respectively. This fact revealed that not only the size but the spacial disposition of the  $N_{3}$ -substituent affect the reduction process.

From a synthetic point of view, reduction of  $N_{3}$ -unsubstituted spirohydantoins with LAH could be a good method to prepare spiroimidazolidin-2<sup>-</sup>-ones. This way would be easier than that proposed by Granger et al.<sup>12)</sup> and Hardy et al.<sup>17)</sup> from cycloketones. It would be also the only method to obtain pure isomeric spiroimidazolidin-2<sup>-</sup>-ones when  $\propto$  and  $\beta$ -spirohydantoins, obtained by Bucherer and Read<sup>18,19)</sup>, were used as starting material. Table I Results obtained in the reduction of spirohydantoins with LAH

Starting spirohydantoin Reaction products NR - NR ν ĊO M.R.<sup>d</sup> Compd. No. Compd. No. R х Y Yield 🗶 bp (mmHg) mр A  $\mathbf{H}^{\mathbf{a}}$ сн, со I 1:4 IX 63 210-211° н<sup>a</sup> сн, со II 1:4 X 52 220-221° н<sup>а</sup> 111 1:4 ХI сн, со 52 193-195° сн,с,н, 80-84°(0.3) CH2 CH2 58 IV 1:4 XII CH2C6H5 100-105°(0.5) v XIII сн, сн, 60 1:4 n-(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub><sup>b</sup> 1:4 85-90°(0.5) VI X¥V CH, CH, 27 CH3 сн, сн, 58-60°(0.2) 1:4 XV 40 VII CH\_C\_H\_b VIII XVI CH, CH2 28 80-83°(0.2) 1:4

a:Prepared by Bucherer synthesis, ref. 18; b:Prepared following a general procedure of N<sub>3</sub>--substitution of hydantoins, ref. 20; c:Prepared according to ref. 21; d:Molar ratio of spirohydantoin to LAH.

## References and Notes

1.	F. J. Wilk and W. J. Close, <u>J. Org. Chem</u> ., 1950, <u>15</u> , 1020.
2.	F. J. Marshall, <u>J. Am. Chem. Soc</u> ., 1956, <u>78</u> , 3696.
3.	V. M. Mićović and M. L. Mihailović, <u>J. Org. Chem</u> ., 1953, <u>18</u> , 1190.
4.	(IX): ir) <sup>KBr</sup> cm <sup>-1</sup> : 3240, 3200 (NH); 1717 (C=0); nmr (CDCl <sub>3</sub> ) § 5.75 (1H,s,N <sub>3</sub> -H), 3.17 (1H,s,
	N <sub>1</sub> H), 3.30 (2H,s,C <sub>5</sub> -H <sub>2</sub> ), 1.70 (8H,s).
F	$(\pi)_{1} = \frac{1}{2} (350 (10) 1607 (20) = (0001) 55560 (10 - 10 - 10) 515 (10 - 10 - 10) 515 (10 - 10 - 10) 515 (10 - 10 - 10) 515 (10 - 10 - 10) 515 (10 - $

5. (X):  $ir \sqrt{max} cm^{-1}$ : 3250 (NH), 1697 (C=0); nmr (CDC1<sub>3</sub>)  $\partial$  5.60 (1H,s,N<sub>3</sub>-H), 5.15 (1H,s,N<sub>1</sub>-H)

3.17 (2H,s,C<sub>5</sub>,H<sub>2</sub>), 1.50 (10H,s).

- 6.  $(XI): ir \sqrt{\frac{KBr}{max}} cm^{-1}: 3350, 3200 (NH), 1700 (C=0); nmr (CDC1<sub>3</sub>) <math>\delta$  5.40 (2H,s,N<sub>1</sub>,H, N<sub>3</sub>,H), 3.20 (2H,s,C<sub>5</sub>,H<sub>2</sub>), 2.30 (2H,m, w<sup>1</sup>/<sub>2</sub> 16Hz), 2.00-1.50 (10H,m).
- 7. (XII):  $ir \sqrt{\frac{Film}{max}} cm^{-1}$ : 3320 (NH); nmr (CCl<sub>4</sub>)  $\delta$  7.10 (5H,s,C<sub>6</sub>H<sub>5</sub>), 3.65 (2H,s,C<sub>H<sub>2</sub></sub>C<sub>6</sub>H<sub>5</sub>), 2.40 (2H,s,C<sub>2</sub>-H<sub>2</sub>), 2.10 (2H,s,C<sub>5</sub>-H<sub>2</sub>), 1.60 (1H,s,NH), 1.45 (8H,s).
- 8. (XIII):  $ir \partial_{max}^{Film} cm^{-1}$ : 3320 (NH); nmr (CC1<sub>4</sub>)  $\delta$  7.17 (5H,s,C<sub>6</sub>H<sub>5</sub>), 3.67 (2H,s, CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>), 2.35 (2H,s,C<sub>2</sub>-H<sub>2</sub>), 2.05 (2H,s,C<sub>5</sub>-H<sub>2</sub>), 1.60 (1H,s,NH), 1.35 (10H,s).
- 9.  $(XIV): ir \sqrt[3]{Film} cm^{-1}: 3320$  (NH); nmr (CC1<sub>4</sub>)  $\delta$  2.59 (2H,t, J=4Hz, NCH<sub>2</sub>), 2.30 (2H,s,C<sub>2</sub>-H<sub>2</sub>), 2.15 (2H,s,C<sub>5</sub>-H<sub>2</sub>), 1.40 (10H,s), 1.22 (1H,s,NH), 1.25-0.85 (7H,m,CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>).
- 10. (XV):  $ir \int_{max}^{Film} cm^{-1}$ : 3320 (NH); nmr (CC1<sub>4</sub>)  $\delta$  2.29 (3H,s,NCH<sub>3</sub>), 2.21 (2H,s,C<sub>2</sub>-H<sub>2</sub>), 2.00 (2H, s,C<sub>5</sub>-H<sub>2</sub>), 1.29 (10H,s), 1.00 (1H,s,NH).
- 11. (XVI):  $ir \sqrt{\lim_{max}} cm^{-1}$ : 3320 (NH); nmr (CCl<sub>4</sub>) § 7.50 (5H,s,C<sub>6</sub>H<sub>5</sub>), 3.58 (2H,s,C<sub>H<sub>2</sub></sub>C<sub>6</sub>H<sub>5</sub>), 2.15 (2H,s,C<sub>2</sub>-H<sub>2</sub>), 2.05 (2H,s,C<sub>5</sub>-H<sub>2</sub>), 2.10 (2H,m, C<sub>1(5)</sub>H), 1.63 (10H,m), 1.15 (1H,s,NH).
- 12. R. Granger, H. Orzalesi and Y. Robbe, <u>Trav. Soc. Pharm. Montpellier</u>, 1968, <u>57</u>, 57.
- 13. R. Granger, H. Orzalesi and Y. Robbe, Trav. Soc. Pharm. Montpellier, 1964, 24, 244.
- 14. W. Ried and F. Muller, <u>Chem.Ber.</u>, 1952, <u>85</u>, 470.
- G. Littieri, A. Larizza, G. Brancaccio and P. Monforte, <u>Atti. Soc. Peloritana Sci. Fis.</u> <u>Mat. Nat.</u>, 1978, <u>24</u>, 77.
- 16. A. Larizza, G. Brancaccio and G. Littieri, J. Org. Chem., 1964, 39, 3697.
- 17. R. J. Hardy, W. S. Lindsay and G. C. Hees, British Patent, 997, 826; C. A., 1965, 63, 13076b.
- 18. H. T. Bucherer and V. A. Lieb, <u>J. Prakt. Chem</u>., 1934, <u>141</u>, 5.
- 19. W. T. Read, J. Am. Chem. Soc., 1922, 44, 1746.
- 20. J. W. Shaffer, E. Stemberg, V. Krimsley and M. B. Winstead, J. Med. Chem., 1968, 11, 462.
- 21. W. Olfield and C. H. Cashin, J. Med. Chem., 1965, 8, 239.

Received, 13th May, 1981